In November, a team of scientists at Nanobac Pharmaceuticals utilizing CytoViva released the first-ever live video footage of calcifying nanoparticles
Nanobac's Director of Science Neva Ciftcioglu added: "The continuation of our collaborative research with NASA will give us an opportunity to stay with exceptionally experienced diverse scientific members helping us to complete the biological definition of the unique agent: calcifying nanoparticles
is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles
(CNPs), formerly known as nanobacteria.
Olavi Kajander, lead scientists with Nanobac Pharmaceuticals, as well as two other works by Mayo researchers, which provide evidence that calcifying nanoparticles
might be infectious and spark calcification in disease.
OTCBB:NNBP) is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles
stated, "We are thrilled with the recent preliminary results we are obtaining at Nanobac bringing new scientific support to earlier findings that the pathophysiology of calcification in vascular and other organ systems involving calcifying nanoparticles
New Study Reveals Distinction Between Calcifying Nanoparticles
and Inorganic Crystals
OTCBB:NNBP) ("Nanobac" or "the Company") have published a new outlook on the role of calcifying nanoparticles
(CNPs) in diseases such as atherosclerosis and kidney stones, setting the groundwork for what company officials call a "significant" announcement next week.
The company's focus is on developing methods to treat calcifying nanoparticles
(CNPs), and by doing so, find more effective approaches to treating and preventing the cardiovascular, kidney and prostate diseases associated with them.
is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles
(CNPs), otherwise known as "nanobacteria.
OTCBB:NNBP - News; "Nanobac" or "the Company") and Mayo Clinic have reached an agreement to study whether calcifying nanoparticles
, already found in atherosclerotic plaque, are infectious and contribute to the onset of heart disease.
Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles
(CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals.